Abstract
We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.
Original language | English |
---|---|
Pages (from-to) | 173 - 180 |
Number of pages | 8 |
Journal | Antiviral Therapy |
Volume | 16 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2011 |